ADHD drug gets 23.5% production boost from DEA amid shortage
The DEA increased the Vyvanse production quota by 23.5% to 32,736 kg due to shortages caused by manufacturing delays and rising demand, with a significant portion allocated for exports.
Read original article
The Drug Enforcement Administration (DEA) has announced a 23.5% increase in the production quota for Vyvanse (lisdexamfetamine) and its generics, raising the total from 26,500 kg to 32,736 kg. This decision comes as the supply of Vyvanse has been strained due to a combination of manufacturing delays and rising demand, particularly following the expiration of Takeda's patent and the introduction of generics. The FDA had previously requested this quota increase to address the ongoing shortages. While the Adderall supply is recovering, the Vyvanse shortage has persisted since June 2023, exacerbated by manufacturers not fully utilizing their production allotments. The DEA noted that only about 70% of the allotted quota for amphetamines was sold, indicating potential inefficiencies in production. Additionally, the DEA's data revealed a significant increase in exports of lisdexamfetamine, with only a quarter of the new quota intended for domestic use. The agency aims to ensure an adequate supply for both domestic and international markets, responding to the growing need for ADHD medications.
- The DEA has increased the Vyvanse production quota by 23.5% to address shortages.
- The shortage of Vyvanse has been attributed to manufacturing delays and increased demand.
- Only 70% of the allotted production quota for amphetamines has been utilized by manufacturers.
- A significant portion of the new quota is designated for international exports rather than domestic supply.
- The FDA and DEA are collaborating to improve production efficiency among manufacturers.
Related
Next-generation psychedelics: should new agents skip the trip?
Companies are investing in next-generation psychedelics to enhance mental health treatment, focusing on reducing psychoactive effects while maintaining therapeutic benefits. Despite expanding interest and investments, questions persist about efficacy and cost-effectiveness.
'Skinny jabs': weight-loss drugs set for new boom as generic versions emerge
Medicines like Wegovy and Saxenda, known as "skinny jabs," are gaining popularity for weight loss. Generic versions, like Teva's generic Victoza, are expected to increase accessibility and affordability, benefiting a broader population. Novo Nordisk invests $4 billion to meet rising demand.
Adderall Shortage Caused by DEA Quotas on Controlled Substances
The Adderall shortage, linked to DEA quotas, impacts ADHD patients. Despite efforts to address the issue, the DEA's inflexible approach exacerbates the crisis, prompting calls for systemic reform to alleviate suffering.
The only doctor prescribed videogame for ADHD
EndeavorRx is an FDA-authorized video game for children with ADHD, part of a therapy program. It improves attention with no serious side effects reported. Cost is $99 for 30 days.
New Painkiller Could Bring Relief to Millions–Without Addiction Risk
Vertex Pharmaceuticals is developing suzetrigine, a non-addictive pain medication that blocks sodium channels, reducing acute pain by 50%. It is under FDA review amid the ongoing opioid crisis.
2 commentsVyvanse (lisdexamfetamine), its generic versions, and d-amphetamine, which is needed for production of lisdexamfetamine.
Related
Next-generation psychedelics: should new agents skip the trip?
Companies are investing in next-generation psychedelics to enhance mental health treatment, focusing on reducing psychoactive effects while maintaining therapeutic benefits. Despite expanding interest and investments, questions persist about efficacy and cost-effectiveness.
'Skinny jabs': weight-loss drugs set for new boom as generic versions emerge
Medicines like Wegovy and Saxenda, known as "skinny jabs," are gaining popularity for weight loss. Generic versions, like Teva's generic Victoza, are expected to increase accessibility and affordability, benefiting a broader population. Novo Nordisk invests $4 billion to meet rising demand.
Adderall Shortage Caused by DEA Quotas on Controlled Substances
The Adderall shortage, linked to DEA quotas, impacts ADHD patients. Despite efforts to address the issue, the DEA's inflexible approach exacerbates the crisis, prompting calls for systemic reform to alleviate suffering.
The only doctor prescribed videogame for ADHD
EndeavorRx is an FDA-authorized video game for children with ADHD, part of a therapy program. It improves attention with no serious side effects reported. Cost is $99 for 30 days.
New Painkiller Could Bring Relief to Millions–Without Addiction Risk
Vertex Pharmaceuticals is developing suzetrigine, a non-addictive pain medication that blocks sodium channels, reducing acute pain by 50%. It is under FDA review amid the ongoing opioid crisis.